Loading organizations...

Peloton Therapeutics is a technology company.
Peloton Therapeutics was a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule cancer therapies. The firm’s primary focus was on targeting hypoxia-inducible factor-2α (HIF-2α), a key protein driver in various cancers. Its lead program, belzutifan (formerly PT2977), advanced as a selective HIF-2α inhibitor, aiming to address the needs of patients with Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma and other HIF-2α driven tumors.
The company was co-founded around 2010 by distinguished scientists Steven L. McKnight, Ph.D., and Michael S. Brown. Dr. McKnight, a renowned expert in gene regulation, along with Dr. Brown, leveraged their deep scientific insights, particularly from their work at UT Southwestern Medical Center, to establish Peloton. Their foundational insight centered on the critical role of HIF-2α in oncology and the potential for targeted small molecule intervention.
Peloton Therapeutics developed therapeutics intended for patients with specific, often difficult-to-treat cancers where HIF-2α played a pivotal role. The company’s overarching vision was to translate groundbreaking academic research into innovative medicines that could offer significant clinical benefit and new treatment paradigms for cancer patients, moving from fundamental biological understanding to practical therapeutic solutions.
Peloton Therapeutics has raised $298.2M across 6 funding rounds.
Peloton Therapeutics has raised $298.2M in total across 6 funding rounds.
Peloton Therapeutics is a clinical‑stage biotechnology company (not a general “technology company”) that developed first‑in‑class small‑molecule inhibitors of HIF‑2α for renal cell carcinoma and related diseases and was acquired by Merck in 2019[1][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Biotech Landscape
Quick Take & Future Outlook
If you’d like, I can:
Peloton Therapeutics has raised $298.2M in total across 6 funding rounds.
Peloton Therapeutics's investors include Derek DiRocco, 305 Ventures, Foresite Capital, RA Capital, The Column Group, Gregory Bailey, BVF Partners, Curative Ventures, Driehaus Capital Management, EcoR1 Capital, Eventide Asset Management, Nextech Invest.
Peloton Therapeutics has raised $298.2M across 6 funding rounds. Most recently, it raised $150.0M Series E in February 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2019 | $150.0M Series E | Derek DiRocco | 305 Ventures, Foresite Capital, RA Capital, The Column Group, Gregory Bailey, BVF Partners, Curative Ventures, Driehaus Capital Management, EcoR1 Capital, Eventide Asset Management, Nextech Invest, OrbiMed, Tichenor Ventures, Topspin Fund, Vida Ventures |
| Jan 1, 2019 | $50.0M Series E | Endeavor Venture Funds | |
| Mar 14, 2017 | $22.2M Series D Extension | ||
| Sep 1, 2016 | $52.0M Series D | Jim Tananbaum | The Column Group, Nextech Invest, Remeditex Ventures, Tichenor Ventures, Topspin Fund |
| Jul 1, 2011 | $18.0M Series A | The Column Group | John Creecy |
| Jun 1, 2011 | $6.0M Series A | Endeavor Venture Funds |